Characterization of Treatments and Disease Course for Women with Breast Cancer Brain Metastases: 5-Year Retrospective Single Institution Experience

Figures & data

Table 1 Baseline Patient Characteristics and OS

	All Subtypes n=98	HR+HER2– n=39	HR+HER2+ n=29	HR–HER2+ n=15	TNBC n=15
Median age at breast cancer diagnosis (range) – years	49 (27–89)	48 (29–89)	51 (28–70)	50 (27–80)	48 (35–75)
Relapsed MBC – no (%)	79 (100)	30 (38.0)	24 (30.4)	12 (15.2)	13 (16.4)
De novo MBC – no (%)	19 (100)	9 (47.4)	5 (26.3)	3 (15.8)	2 (10.5)
Median time to BM from diagnosis of MBC (range) – months		17 (0–130)	10 (0–78)	12 (0–49)	3 (0–30)
Median Breast-GPA score		1.0	2.5	2.5	0.5
Median OS from diagnosis of BM (range) – months		3 (1–47)	8 (1–118)	7 (1–46)	2 (1–26)

Abbreviations: BM, brain metastases; GPA, Graded Prognostic Assessment; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; OS, overall survival; TNBC, triple negative breast cancer.

Table 2 Treatment Received After Diagnosis of BM

	All Subtypes n=69	HR+HER2– n=26	HR+HER2+ n=23	HR–HER2+ n=12	TNBC n=8
Patients who received systemic treatment after diagnosis of BM – no (%)	45 (100)	16 (35.6)	16 (35.6)	9 (20.0)	4 (8.8)
Median no. of systemic treatments after diagnosis of BM (range)		2 (1–5)	2 (1–3)	1 (1–6)	1 (1–3)
Patients who received local treatment after diagnosis of BM – no (%)	69 (100)	26 (37.7)	23 (33.3)	12 (17.4)	8 (11.6)
Median no. of local treatments after diagnosis of BM (range)		1 (1–2)	1 (1–3)	1 (1–2)	1 (1–3)

Abbreviations: BM, brain metastases; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer.

Table 3 Types of Local Treatment for BM in the First Line

First Line Local Treatments for BM – no (%)	All Subtypes n=69	HR+HER2– n=26	HR+HER2+ n=23	HR–HER2+ n=12	TNBC n=8
WBRT	48 (69.6)	22 (84.7)	16 (69.6)	7 (58.3)	3 (37.5)
SRS	6 (8.7)	1 (3.8)	3 (13.0)	0 (0)	2 (25.0)
Surgery	15 (21.7)	3 (11.5)	4 (17.4)	5 (49.7)	3 (27.5)

Abbreviations: BM, brain metastases; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; SRS, stereotactic radiosurgery; TNBC, triple negative breast cancer; WBRT, whole brain radiotherapy.

Figure 1 Kaplan–Meier curve for survival by tumour subtype.

Abbreviations: BM, brain metastases; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; mo, month; OS, overall survival; TNBC, triple negative breast cancer.

Figure 2 Kaplan–Meier curve for survival by GPA category.

Abbreviations: BM, brain metastases; GPA, Graded Prognostic Assessment; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; mo, month; OS, overall survival; TNBC, triple negative breast cancer.